Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Nutraplus India's 3-Year RORE % for the quarter that ended in Mar. 2026 was 40.63%.
The industry rank for Nutraplus India's 3-Year RORE % or its related term are showing as below:
BOM:524764's 3-Year RORE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.82
vs BOM:524764: 40.63
Nutraplus India (BOM:524764) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Nutraplus India 3-Year RORE % Related Terms
Nutraplus India 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Nutraplus India's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nutraplus India's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutraplus India 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nutraplus India's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Nutraplus India's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Nutraplus India (BOM:524764) has a 3-Year RORE % of 40.63 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Nutraplus India and its competitors.
Is Nutraplus India's 3-Year RORE % too high?
Nutraplus India's current 3-Year RORE % is 40.63. The Drug Manufacturers industry median 3-Year RORE % is 2.82. Nutraplus India's value of 40.63 is 1340.8% above this industry median.
How does Nutraplus India's 3-Year RORE % compare to ZTS?
Nutraplus India's 3-Year RORE % of 40.63 can be compared against companies in the Drug Manufacturers industry. The industry median 3-Year RORE % is 2.82. Nutraplus India's value of 40.63 is 1340.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 2.82, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nutraplus India's current 3-Year RORE % of 40.63 is 1340.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Nutraplus India and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutraplus India's current 3-Year RORE % is 40.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutraplus India stock overvalued right now?
Nutraplus India (BOM:524764) has a current 3-Year RORE % of 40.63. The current 3-Year RORE % is 40.63 and 1340.8% above the Drug Manufacturers industry median of 2.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Nutraplus India (BOM:524764), the current 3-Year RORE % is 40.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nutraplus India Ltd is an India based company engaged in manufacturing of active pharmaceutical ingredients (API), intermediates and contract manufacturing of intermediates. It produces bulk drugs, and specialty chemicals and intermediates. The company's product portfolio encompasses therapeutic categories like analgesic, anti-asthma, antimalarial, anti-protozoan infections, mucolyting agent, and antihelmintic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524764 has been successfully added to your 
